Search Results - "Callies, Sophie"

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer by Bendell, Johanna C, Varghese, Anna M, Hyman, David M, Bauer, Todd M, Pant, Shubham, Callies, Sophie, Lin, Ji, Martinez, Ricardo, Wickremsinhe, Enaksha, Fink, Aaron, Wacheck, Volker, Moore, Kathleen N

“…The PI3K/mTOR pathway is frequently aberrated in cancer. LY3023414 is a potent and selective ATP-competitive inhibitor of class I PI3K isoforms, mTOR, and…”
Get full text

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma by Zauderer, Marjorie G., Alley, Evan W., Bendell, Johanna, Capelletto, Enrica, Bauer, Todd M., Callies, Sophie, Szpurka, Anna M., Kang, Suhyun, Willard, Melinda D., Wacheck, Volker, Varghese, Anna M.

“…Summary BACKGROUND LY3023414 is a selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1/2 and DNA-PK. A Phase 1 dose escalation, 200 mg twice…”
Get full text

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia by Vadhan-Raj, Saroj, Abonour, Rafat, Goldman, Jonathan W, Smith, David A, Slapak, Christopher A, Ilaria, Jr, Robert L, Tiu, Ramon V, Wang, Xuejing, Callies, Sophie, Cox, Joanne, Tuttle, Jay L, Lau, Yiu-Keung, Roeland, Eric J

“…Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin…”
Get full text

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study by TALBOT, Denis C, RANSON, Malcolm, MCHUGH, Peter J, DE BONO, Johann S, MATTHEWS, Julian, SALEEM, Azeem, PRICE, Patricia, DAVIES, Joanna, LAHN, Michael, CALLIES, Sophie, ANDRE, Valérie, KADAM, Sunil, BURGESS, Michael, SLAPAK, Christopher, OLSEN, Anna L

“…Enhanced tumor cell survival through expression of inhibitors of apoptosis (IAP) is a hallmark of cancer. Survivin, an IAP absent from most normal tissues, is…”
Get full text

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study by Veltkamp, Stephan A, Jansen, Robert S, Callies, Sophie, Pluim, Dick, Visseren-Grul, Carla M, Rosing, Hilde, Kloeker-Rhoades, Susanne, Andre, Valerie A M, Beijnen, Jos H, Slapak, Christopher A, Schellens, Jan H M

“…Purpose: To determine the toxicity, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral gemcitabine…”
Get full text

Association of Long-term Administration of the Survivin mRNA-Targeted Antisense Oligonucleotide LY2181308 With Reversible Kidney Injury in a Patient With Metastatic Melanoma by Herrington, William G., MRCP, Talbot, Denis C., PhD, Lahn, Michael M., MD, Brandt, John T., MD, Callies, Sophie, PhD, Nagle, Ray, MD, Winearls, Christopher G., DPhil, Roberts, Ian S.D., FRCPath

“…A 57-year-old man with metastatic melanoma was treated with the survivin inhibitor and antisense oligonucleotide LY2181308 as part of a First-in-Human Dose…”
Get full text

Elimination of [14C] LY3023414 by aldehyde oxidase and CYP enzymes in humans following oral administration by Zhou, Lian, Satonin, Darlene, Chappell, Jill, Yi, Ping, Moulton, Richard, Callies, Sophie, Cassidy, Kenneth

Get full text

Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients by Saleem, Azeem, Matthews, Julian C, Ranson, Malcolm, Callies, Sophie, André, Valérie, Lahn, Michael, Dickinson, Claire, Prenant, Christian, Brown, Gavin, McMahon, Adam, Talbot, Denis C, Jones, Terry, Price, Patricia M

“…Antisense oligonucleotides (ASOs) have potential as anti-cancer agents by specifically modulating genes involved in tumorigenesis. However, little is known…”
Get full text

A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979) by CALLIES, Sophie, DE ALWIS, Dinesh P, WRIGHT, James G, SANDLER, Alan, BURGESS, Michael, AARONS, Leon

“…To develop a population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of zosuquidar.3HCl, a potent P-glycoprotein inhibitor. The…”
Get full text

Children’s strategies in complex arithmetic by Lemaire, Patrick, Callies, Sophie

“…Strategies used to solve two-digit addition problems (e.g., 27 + 48, Experiment 1) and two-digit subtraction problems (e.g., 73 – 59, Experiment 2) were…”
Get full text

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship by Nakagawa, Kazuhiko, Garon, Edward B., Gao, Ling, Callies, Sophie, Zimmermann, Annamaria, Walgren, Richard, Visseren-Grul, Carla, Reck, Martin

“…Purpose In RELAY, ramucirumab plus erlotinib (RAM + ERL) improved progression-free survival (PFS) in patients with untreated, metastatic, EGFR-mutated,…”
Get full text

Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease by Sheetz, Matthew, Barrington, Philip, Callies, Sophie, Berg, Paul H., McColm, Juliet, Marbury, Thomas, Decker, Brian, Dyas, Gregory L., Truhlar, Stephanie M.E., Benschop, Robert, Leung, Donmienne, Berg, Jolene, Witcher, Derrick R.

“…Aims Erythropoiesis‐stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse…”
Get full text

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer by Sweeney, Christopher J, Percent, Ivor J, Babu, Sunil, Cultrera, Jennifer L, Mehlhaff, Bryan A, Goodman, Oscar B, Morris, David S, Schnadig, Ian D, Albany, Costantine, Shore, Neal D, Sieber, Paul R, Guba, Susan C, Zhang, Wei, Wacheck, Volker, Donoho, Gregory P, Szpurka, Anna M, Callies, Sophie, Lin, Boris Kin, Bendell, Johanna C

“…To report efficacy and safety of samotolisib (LY3023414; PI3K/mTOR dual kinase and DNA-dependent protein kinase inhibitor) plus enzalutamide in patients with…”
Get full text

Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials by Llovet, Josep M, Singal, Amit G, Villanueva, Augusto, Finn, Richard S, Kudo, Masatoshi, Galle, Peter R, Ikeda, Masafumi, Callies, Sophie, McGrath, Louise M, Wang, Chunxiao, Abada, Paolo, Widau, Ryan C, Gonzalez-Gugel, Elena, Zhu, Andrew X

“…Ramucirumab is an effective treatment for patients with advanced hepatocellular carcinoma (aHCC) and baseline alpha-fetoprotein (AFP) ≥400 ng/mL. We aimed to…”
Get full text

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer by HONG, David S, KURZROCK, Razelle, HOLZER, Timothy R, MERIC-BERNSTAM, Funda, FISHMAN, Mayer, SIMON, George, YUN OH, WHELER, Jennifer, NAING, Aung, BRAIL, Les, CALLIES, Sophie, ANDRE, Valérie, KADAM, Sunil K, NASIR, Aejaz

“…The antisense oligonucleotide LY2275796 blocks expression of cap-binding protein eukaryotic initiation factor 4E (eIF-4E), an mRNA translation regulator…”
Get full text

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer by Yap, Timothy A, Vieito, Maria, Baldini, Capucine, Sepúlveda-Sánchez, Juan Manuel, Kondo, Shunsuke, Simonelli, Matteo, Cosman, Rasha, van der Westhuizen, Andre, Atkinson, Victoria, Carpentier, Antoine F, Löhr, Mario, Redman, Rebecca, Mason, Warren, Cervantes, Andres, Le Rhun, Emilie, Ochsenreither, Sebastian, Warren, Louise, Zhao, Yumin, Callies, Sophie, Estrem, Shawn T, Man, Michael, Gandhi, Leena, Avsar, Emin, Melisi, Davide

“…A novel, selective, next-generation transforming growth factor beta (TGFβ) receptor type-1 small molecule inhibitor, LY3200882, demonstrated promising…”
Get full text

Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor by Klippel, Anke, Wang, Rui, Puca, Loredana, Faber, Andrew Lee, Shen, Weihua, Bhagwat, Shripad V., Karukurichi, Kannan, Zhang, Feiyu Fred, Perez, Carmen, Rama, Ramon, Ramos, Ana, Zheng, Yi, Bonday, Zahid, Thomas, James, Brooks, Harold B., Kindler, Lisa J., Bogner, Sarah M., Zolfaghari, Parisa, II, Mark Hicks, Callies, Sophie, Mattioni, Brian, LeBrun, Laurie, Durbin, Jim, Anderson, Erin, Mayne, Chris, Kesicki, Edward, Kolakowski, Gabrielle, Andrews, Steven W., Brandhuber, Barbara J.

“…Abstract Phosphoinositide 3-kinase alpha (PI3Kα) H1047R mutations are activating oncogenic events that occur in ~15% of advanced breast cancers. While there is…”
Get full text

A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer by Wiechno, Paweł, Somer, Bradley G, Mellado, Begoña, Chłosta, Piotr L, Cervera Grau, José Manuel, Castellano, Daniel, Reuter, Christoph, Stöckle, Michael, Kamradt, Jörn, Pikiel, Joanna, Durán, Ignacio, Wedel, Steffen, Callies, Sophie, André, Valérie, Hurt, Karla, Brown, Jacqueline, Lahn, Michael, Heinrich, Bernhard

“…Abstract Castration-resistant prostate cancer (CRPC) is partially characterised by overexpression of antiapoptotic proteins, such as survivin. In this phase 2…”
Get full text

Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients by Varghese, Anna M., Moore, Kathleen N., Hamilton, Erika Paige, Hyman, David Michael, Jhaveri, Komal L., Wang, Xuejing Aimee, Callies, Sophie, Fink, Aaron Alan, Wacheck, Volker, Bendell, Johanna C.

“…Abstract only 1064 Background: Thephosphatidylinositol 3-kinase (PI3K) /mammalian target of rapamycin (mTOR) pathway is frequently activated in breast cancer…”
Get full text

Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone by Sweeney, Christopher, Percent, Ivor John, Babu, Sunil, Cultrera, Jennifer, Mehlhaff, Bryan Allyn, Goodman, Oscar B., Morris, David, Schnadig, Ian D., Albany, Costantine, Shore, Neal D., Sieber, Paul R, Guba, Susan, Wang, Minmin, Kang, Suhyun, Wacheck, Volker, Donoho, Gregory P, Szpurka, Anna M., Callies, Sophie, Lin, Boris K., Bendell, Johanna C.

“…Abstract only 5009 Background: Preclinical and phase 1 results suggest PI3K/mTOR pathway inhibition may enhance androgen receptor inhibition. We report the…”
Get full text